 Allergan, an AbbVie Inc NYSE: ABBV, has submitted a marketing application to the FDA for investigational AGN-190584 pilocarpine 1.25 ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021. 